Veru reports positive safety results from phase 2b quality study: enobosarm added to semaglutide led to greater fat loss, preservation of muscle, and fewer gastrointestinal side effects compared to semaglutide alone

--phase 2b quality clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --based on phase 2b quality trial efficacy and safety data, enobosarm 3mg will advance as the proposed oral dose for the phase 3 clinical program-- -- enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects (diarrhea, nausea, and gerd) compared to semaglutide alone--
VERU Ratings Summary
VERU Quant Ranking